These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21321981)

  • 1. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study.
    Karkera J; Steiner H; Li W; Skradski V; Moser PL; Riethdorf S; Reddy M; Puchalski T; Safer K; Prabhakar U; Pantel K; Qi M; Culig Z
    Prostate; 2011 Sep; 71(13):1455-65. PubMed ID: 21321981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
    Fizazi K; De Bono JS; Flechon A; Heidenreich A; Voog E; Davis NB; Qi M; Bandekar R; Vermeulen JT; Cornfeld M; Hudes GR
    Eur J Cancer; 2012 Jan; 48(1):85-93. PubMed ID: 22129890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328.
    Steiner H; Cavarretta IT; Moser PL; Berger AP; Bektic J; Dietrich H; Zaki MH; Nakada M; Hobisch A; Nemeth JA; Culig Z
    Prostate; 2006 Dec; 66(16):1744-52. PubMed ID: 16998813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
    Zerbini LF; Wang Y; Cho JY; Libermann TA
    Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer.
    Guo Y; Nemeth J; O'Brien C; Susa M; Liu X; Zhang Z; Choy E; Mankin H; Hornicek F; Duan Z
    Clin Cancer Res; 2010 Dec; 16(23):5759-69. PubMed ID: 20699329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.
    Hobisch A; Eder IE; Putz T; Horninger W; Bartsch G; Klocker H; Culig Z
    Cancer Res; 1998 Oct; 58(20):4640-5. PubMed ID: 9788616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
    Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
    Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway.
    Lee SO; Lou W; Johnson CS; Trump DL; Gao AC
    Prostate; 2004 Aug; 60(3):178-86. PubMed ID: 15176047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity.
    Giménez-Bonafé P; Fedoruk MN; Whitmore TG; Akbari M; Ralph JL; Ettinger S; Gleave ME; Nelson CC
    Prostate; 2004 May; 59(3):337-49. PubMed ID: 15042610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
    Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice.
    Smith PC; Keller ET
    Prostate; 2001 Jun; 48(1):47-53. PubMed ID: 11391686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling.
    Mink SR; Hodge A; Agus DB; Jain A; Gross ME
    Prostate; 2010 Aug; 70(11):1201-10. PubMed ID: 20564426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.
    Wallner L; Dai J; Escara-Wilke J; Zhang J; Yao Z; Lu Y; Trikha M; Nemeth JA; Zaki MH; Keller ET
    Cancer Res; 2006 Mar; 66(6):3087-95. PubMed ID: 16540658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells.
    Bass R; Perry B; Langenstroer P; Thrasher JB; Dennis KL; Tawfik O; Holzbeierlein J
    J Urol; 2009 Feb; 181(2):615-9; discussion 619-20. PubMed ID: 19091346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
    Hobisch A; Ramoner R; Fuchs D; Godoy-Tundidor S; Bartsch G; Klocker H; Culig Z
    Clin Cancer Res; 2001 Sep; 7(9):2941-8. PubMed ID: 11555613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase.
    Godoy-Tundidor S; Cavarretta IT; Fuchs D; Fiechtl M; Steiner H; Friedbichler K; Bartsch G; Hobisch A; Culig Z
    Prostate; 2005 Jul; 64(2):209-16. PubMed ID: 15712220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways.
    Park JI; Lee MG; Cho K; Park BJ; Chae KS; Byun DS; Ryu BK; Park YK; Chi SG
    Oncogene; 2003 Jul; 22(28):4314-32. PubMed ID: 12853969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma.
    Puchalski T; Prabhakar U; Jiao Q; Berns B; Davis HM
    Clin Cancer Res; 2010 Mar; 16(5):1652-61. PubMed ID: 20179212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms by which interleukin-6 regulates prostate-specific antigen gene expression in prostate LNCaP carcinoma cells.
    Tsui KH; Lin YF; Chen YH; Chang PL; Juang HH
    J Androl; 2011; 32(4):383-93. PubMed ID: 21051589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.